Literature DB >> 19192416

Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials.

Samy I McFarlane1, Jeffrey S Borer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19192416     DOI： 10.1007/s11892-009-0001-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  17 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  S I McFarlane; M Banerji; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 4.  Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

Authors:  Samy I McFarlane; Ashok Kumar; James R Sowers
Journal:  Am J Cardiol       Date:  2003-06-19       Impact factor: 2.778

5.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Authors:  Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman
Journal:  Am Heart J       Date:  2008-10       Impact factor: 4.749

6.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

7.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

8.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

9.  Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.

Authors:  Christos Tikellis; Peter J Wookey; Riccardo Candido; Sof Andrikopoulos; Merlin C Thomas; Mark E Cooper
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

10.  Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance.

Authors:  Katsunori Suzuki; Osamu Nakagawa; Yoshifusa Aizawa
Journal:  Clin Exp Hypertens       Date:  2008-07       Impact factor: 1.749
View more
  1 in total

1.  ONTARGET: use of ramipril, telmisartan, or both in patients with high cardiovascular risks.

Authors:  HoWon Lee; Amgad N Makaryus; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.